Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Mother and Infant Visit Adherence and Treatment Engagement Study (MOTIVATE!)

22 de abril de 2021 atualizado por: University of Colorado, Denver

Maximizing Adherence and Retention for Women and Infants in the Context of Option B+

This is a 2x2 factorial cluster randomized trial of two interventions to improve retention and adherence for women and infants on Option B+. The overall goal is to determine which intervention (or combination of interventions) maximizes antiretroviral therapy (ART) adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.The proposed study will be conducted in rural Nyanza Province, Kenya at 20 low-resource primary health care facilities and associated communities supported by Family AIDS Care and Education Services (FACES), a President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV prevention care, and treatment program, ((AIDS) acquired immune deficiency syndrome, (HIV) human immunodeficiency virus) . The investigators will assess both process and outcome indicators using a 2x2 factorial design, in which equal numbers of clusters will be randomized to one of the interventions (community-based mentor mothers or theory-based mobile text messages), both interventions, or standard of care. The interventions will be added to fully integrated high quality HIV and antenatal, maternal, neonatal, and child health (ANC/MNCH) services already offered at these sites.

Visão geral do estudo

Descrição detalhada

In order to eliminate new pediatric HIV infections, save maternal lives, and simplify antiretroviral therapy (ART) implementation in settings with generalized HIV epidemics, current World Health Organization (WHO) guidance recommends lifelong triple ART for all pregnant and breastfeeding women (Option B+). However, despite the promise of Option B+ to remove logistical barriers and to promote maternal health through life-long ART, this strategy brings challenges. Key amongst these challenges are adherence to ART and continuous retention in HIV care, especially for women who do not require ART for their own health. Barriers to adherence and retention in care for prevention of mother-to-child transmission (PMTCT) have been identified at the individual, interpersonal, community, and health facility levels; yet specific barriers in the context of Option B+ are not well understood. The investigators' study will be conducted at 20 health facilities and associated communities in Nyanza Province, Kenya where Mother to Child Transmission (MTCT) rates prior to Option B+ roll-out remained near 10%, despite the wide availability of PMTCT services. As Option B+ is scaled up in Kenya, it is essential to identify effective methods to ensure long-term adherence and retention in care for mother-baby pairs, throughout pregnancy, breastfeeding, and beyond. Building on the investigating team's prior research experience in this setting, the investigators propose to gain understanding of and address potential barriers at the individual, community, and health facility levels through formative research with HIV-positive pregnant and postpartum women, their male partners, and health care providers. This information will be used to refine two proposed interventions that are highly likely to maximize ART adherence and retention in care among HIV-infected pregnant women and HIV-exposed infants. These interventions will be rigorously tested in rural Kenya, using a cluster randomized 2x2 factorial design. The evidence-based interventions to be tested will include 1) community Mentor Mothers (cMM) who will provide support for ART adherence and retention in care for HIV-positive women in the community and 2) individually tailored, theory based mobile phone text messages to help retain women and infants in HIV care. The investigators' overall goal is to determine which intervention (or combination of interventions) maximizes ART adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes. The investigators' primary outcomes will include ART adherence at 12 months postpartum and retention in care, measured by a documented HIV care visit within 90 days prior to 12 months postpartum. Secondary outcomes will include MTCT at 6 weeks, 12 months and 18 months; as well as maternal viral loads and CD4 counts. Results from this study will inform the scale-up of Option B+ in Kenya by identifying effective interventions and combinations of interventions that can reduce barriers and increase facilitators of optimal ART adherence and retention in care with the aims of reaching the elimination of mother to child transmission of HIV and significantly improving maternal health.

Tipo de estudo

Intervencional

Inscrição (Real)

1338

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Nairobi, Quênia
        • Kenya Medical Research Institute

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Age 18 years or older,
  • HIV-infected pregnant women and their HIV-exposed infants pairs,
  • attends the antenatal care (ANC) clinic at one of the study sites.

Exclusion Criteria:

  • Less than 18 years of age,
  • HIV-infected women not currently pregnant,
  • not HIV-infected at the time of the first ANC visit.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição fatorial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: cMM and Text Messaging
Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
Home visits from community mentor mothers
Text messages received on mobile phone
Outro: cMM Only
Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
Home visits from community mentor mothers
Outro: Text Messaging Only
Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
Text messages received on mobile phone
Sem intervenção: Neither cMM nor Text Messaging
Participants randomized to this arm will receive standard of care with no interventions.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Self-reported adherence on antiretroviral therapy
Prazo: 12 months post-partum
Self-report
12 months post-partum
Adherence on antiretroviral therapy
Prazo: 12 months post-partum
Viral load<100 copies/ml based on medical records
12 months post-partum
Adherence on antiretroviral therapy (infant)
Prazo: 12 months post-partum
Use of ARVs for the infant
12 months post-partum
Retention in care
Prazo: 12 months post-partum
Proportion of women who have an HIV care visit within 90 days at 12 months after the birth
12 months post-partum
Adherence on antiretroviral therapy (dried blood spots)
Prazo: 12 months post-partum
Viral load<100 copies/ml based on dried blood spots
12 months post-partum

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Maternal CD4 count change
Prazo: 6 months after baseline
Change in CD4 count baseline to 6 months after baseline
6 months after baseline
Maternal viral load count change
Prazo: 6 months after baseline
Change in viral load from baseline to 6 months after baseline
6 months after baseline
Infant retention in care (feeding method)
Prazo: 12 and 18 months
Infant feeding method
12 and 18 months
Infant retention in care
Prazo: 12 and 18 months
Retention in care through 12 and 18 months
12 and 18 months
Infant retention in care (survival status)
Prazo: 12 and 18 months
Survival status of infant
12 and 18 months
Uptake of intervention services (Number/types of text messages sent)
Prazo: 3 years
Number/types of text messages sent
3 years
Uptake of intervention services (receipt of text messages)
Prazo: 3 years
Receipt of text messages
3 years
Uptake of intervention services (home visits)
Prazo: 3 years
Number of home visits received
3 years
Uptake of intervention services (support groups attended)
Prazo: 3 years
Number of support groups attended.
3 years
Mother-to-Child-Transmission
Prazo: 6 weeks, 9 months and 18 months
Result of infant HIV test at 6 wks, 9,18 months
6 weeks, 9 months and 18 months
Infant testing
Prazo: 6 weeks, 9 months and 18 months
Uptake and date of infant testing
6 weeks, 9 months and 18 months
Infant enrollment in care
Prazo: 6 weeks
Infant enrollment in HIV care
6 weeks
Male partner involvement
Prazo: 12 months post-partum
Composite variable including Y/N response to indicate if male partner attended a health visit with his female partner, encouraged facility delivery, reminded to take HIV medication, reminded to go for HIV care, provided transport money to go to the clinic/dispensary, reminded to give the infant prophylaxis, helped giving the infant prophylaxis medication, collected medication for the woman or infant, encouraged specific infant feeding, and encouraged pediatric HIV testing. These are assessed in the follow-up questionnaires completed at 12 months post-partum.
12 months post-partum

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Lisa Abuogi, MD, MSc, University of Colorado, Denver

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de maio de 2014

Conclusão Primária (Real)

1 de abril de 2019

Conclusão do estudo (Real)

1 de março de 2021

Datas de inscrição no estudo

Enviado pela primeira vez

11 de março de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de julho de 2015

Primeira postagem (Estimativa)

7 de julho de 2015

Atualizações de registro de estudo

Última Atualização Postada (Real)

26 de abril de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de abril de 2021

Última verificação

1 de abril de 2021

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever